Metabotropic glutamate receptors as novel therapeutic targets on visceral sensory pathways
- PMID: 21472028
- PMCID: PMC3066463
- DOI: 10.3389/fnins.2011.00040
Metabotropic glutamate receptors as novel therapeutic targets on visceral sensory pathways
Abstract
Metabotropic glutamate receptors (mGluR) have a diverse range of structures and molecular coupling mechanisms. There are eight mGluR subtypes divided into three major groups. Group I (mGluR1 and 5) is excitatory; groups II (mGluR2 and 3) and III (mGluR 4, 6, and 7) are inhibitory. All mGluR are found in the mammalian nervous system but some are absent from sensory neurons. The focus here is on mGluR in sensory pathways from the viscera, where they have been explored as therapeutic targets. Group I mGluR are activated by endogenous glutamate or constitutively active without agonist. Constitutive activity can be exploited by inverse agonists to reduce neuronal excitability without synaptic input. This is promising for reducing activation of nociceptive afferents and pain using mGluR5 negative allosteric modulators. Many inhibitory mGluR are also expressed in visceral afferents, many of which markedly reduce excitability. Their role in visceral pain remains to be determined, but they have shown promise in inhibition of the triggering of gastro-esophageal reflux, via an action on mechanosensory gastric afferents. The extent of reflux inhibition is limited, however, and may not reach a clinically useful level. On the other hand, negative modulation of mGluR5 has very potent actions on reflux inhibition, which has produced the most likely candidates so far as therapeutic drugs. These act probably outside the central nervous system, and may therefore provide a generous therapeutic window. There are many unanswered questions about mGluR along visceral afferent pathways, the answers to which may reveal many more therapeutic candidates.
Keywords: gastro-esophageal reflux; lower esophageal sphincter; vagal afferents; visceral pain.
Figures



Similar articles
-
Peripheral versus central modulation of gastric vagal pathways by metabotropic glutamate receptor 5.Am J Physiol Gastrointest Liver Physiol. 2007 Feb;292(2):G501-11. doi: 10.1152/ajpgi.00353.2006. Epub 2006 Oct 19. Am J Physiol Gastrointest Liver Physiol. 2007. PMID: 17053158
-
Metabotropic glutamate receptors inhibit mechanosensitivity in vagal sensory neurons.Gastroenterology. 2005 Feb;128(2):402-10. doi: 10.1053/j.gastro.2004.11.062. Gastroenterology. 2005. PMID: 15685551
-
Anatomy and function of group III metabotropic glutamate receptors in gastric vagal pathways.Neuropharmacology. 2008 May;54(6):965-75. doi: 10.1016/j.neuropharm.2008.02.010. Epub 2008 Feb 19. Neuropharmacology. 2008. PMID: 18371991
-
Group II Metabotropic Glutamate Receptors: Role in Pain Mechanisms and Pain Modulation.Front Mol Neurosci. 2018 Oct 9;11:383. doi: 10.3389/fnmol.2018.00383. eCollection 2018. Front Mol Neurosci. 2018. PMID: 30356691 Free PMC article. Review.
-
Localization and role of metabotropic glutamate receptors subtype 5 in the gastrointestinal tract.World J Gastroenterol. 2017 Jul 7;23(25):4500-4507. doi: 10.3748/wjg.v23.i25.4500. World J Gastroenterol. 2017. PMID: 28740338 Free PMC article. Review.
Cited by
-
The gut as a sensory organ.Nat Rev Gastroenterol Hepatol. 2013 Dec;10(12):729-40. doi: 10.1038/nrgastro.2013.180. Epub 2013 Sep 24. Nat Rev Gastroenterol Hepatol. 2013. PMID: 24061204
-
Tweeters, Woofers and Horns: The Complex Orchestration of Calcium Currents in T Lymphocytes.Front Immunol. 2015 May 21;6:234. doi: 10.3389/fimmu.2015.00234. eCollection 2015. Front Immunol. 2015. PMID: 26052328 Free PMC article. Review.
-
Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder.Curr Neuropharmacol. 2017;15(7):977-995. doi: 10.2174/1570159X15666170320104237. Curr Neuropharmacol. 2017. PMID: 28322166 Free PMC article. Review.
-
Evaluation of Safety, Pharmacokinetic, and Pharmacodynamic Characteristics of a Novel Dual mGluR5/5-HT2AR Antagonist (VVZ-2471) in a Randomized, Double-Blind, First-in-Human Study.CNS Drugs. 2025 Jun;39(6):583-595. doi: 10.1007/s40263-025-01181-9. Epub 2025 Apr 15. CNS Drugs. 2025. PMID: 40234362 Clinical Trial.
-
Chronic stimulation of group II metabotropic glutamate receptors in the medulla oblongata attenuates hypertension development in spontaneously hypertensive rats.PLoS One. 2021 May 19;16(5):e0251495. doi: 10.1371/journal.pone.0251495. eCollection 2021. PLoS One. 2021. PMID: 34010316 Free PMC article.
References
-
- Anderson J. J., Bradbury M. J., Giracello D. R., Chapman D. F., Holtz G., Roppe J., King C., Cosford N. D., Varney M. A. (2003). In vivo receptor occupancy of mGlu5 receptor antagonists using the novel radioligand [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine). Eur. J. Pharmacol. 473, 35–40 - PubMed
-
- Bhave G., Karim F., Carlton S. M., Gereau R. W. (2001). Peripheral group I metabotropic glutamate receptors modulate nociception in mice. Nat. Neurosci. 4, 417–423 - PubMed
LinkOut - more resources
Full Text Sources